Company Analysis
Sign in

Microbot Medical Inc. (MBOT)

Nasdaq: MBOT · Surgical & Medical Instruments & Apparatus · Hingham, MA · filing with the SEC since 1994
Full chart Alerts Compare
Grade2.8
◀ Past 1.8● Present 3.9▶ Future 2.4
3 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

The grade of Microbot Medical Inc.

Nine metrics read from its own filings, by tense
Headline grade
2.8/10
◀ Past1.830% of the headline
● Present3.940% of the headline
▶ Future2.430% of the headline

All three tenses have at least two readings, so the archetype blend applies as printed.

Of the nine metrics, 6 read as filed from the record and 3 are SI estimates, each with its reasoning, its confidence and what would change it on its card.

◀ Past

What did they actually do?

1.8/1030% of the headline grade · 2 of 3 filed, 1 estimated

Surviving crises

as filed
3.1/10

Has it survived what it has been through?

4 warning events since 2017; the latest 2024-10-11.

weight 33% of this tense · 31st percentile among 121 sector filers · read for itself

From the record

Microbot Medical Inc.'s filings since 2017 show 4 warning events of 2 kinds: a notice about its exchange listing (8-K item 3.01, 2 times, the latest 2024-10-11); a late-report notice (Form NT 10-K or NT 10-Q, 2 times, the latest 2023-05-16) (its current reports).

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Track record

as filed
0.8/10

What has it actually done, year after year?

-30% a year over 7 filed years; profit years unseen.

weight 45% of this tense · 8th percentile among 105 sector filers · read for its customers

From the record

Microbot Medical Inc.'s 7 filed years say what it did: revenue went from $993 thousand in fiscal 2009 to $117 thousand in fiscal 2015, down 30% a year; it rose in 3 of 6 years; the deepest fall was 92% from fiscal 2010 to fiscal 2015 (its annual reports).

What it rests on

  • revenue growth over the filed span-30.0%bottom 4% of its family
  • the share of years revenue rosebottom 12% of its family
  • the deepest fall from a revenue peak91.8%bottom 8% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Shareholder treatment

SI estimate
1.8/10

How has it treated the people who own it?

SI estimate 1.8/10, confidence 35 of 100 (one part).

weight 22% of this tense · 18th percentile among 120 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate
Read from one part only, the share count over the years, which ranks in the bottom 18% of 120 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
What the record cannot read
Fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
How it was reasoned
one part: the share count over the years, the one part on file, ranked among 120 in its family.
Confidence
35 of 100
What would change it
A filing that carries the missing parts replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Microbot Medical Inc.'s shareholder treatment is put at 1.8 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the bottom 18% of 120 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.

● Present

What are they doing right now?

3.9/1040% of the headline grade · 3 of 3 filed

Financial health

as filed
5.7/10

Is it financially healthy right now?

ROE -17%: lost 17¢ per shareholder dollar. Leverage 5%: owes 5¢ per asset dollar.

weight 45% of this tense · 57th percentile among 120 sector filers · read for itself

From the record

Return on equity: in the fiscal year ended 2025-12-31, Microbot Medical Inc. lost about 17 cents for every dollar of shareholders' money. Leverage: it owed about 5 cents per dollar of assets, and net share issuance: its share count grew 192.7% over the year (the filed statements).

What it rests on

  • what it owes per dollar of assetstop 3% of its family
  • return on equitytop 41% of its family
  • the share count against the year beforebottom 14% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Industry position

as filed
0.3/10

How strong is its position in its industry?

bottom 3% of 109 in its family.

weight 33% of this tense · 3rd percentile among 109 sector filers · read for its customers

From the record

Microbot Medical Inc.'s standing among 109 graded names in its industry family: revenue of $117 thousand in fiscal 2015 ranks in the bottom 3% by size; revenue growth of -56% a year over the last 3 filed years ranks in the bottom 2% (its annual reports).

What it rests on

  • revenue against the family$116,887bottom 3% of its family
  • three-year revenue growth-56.0%bottom 2% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Leadership

as filed
5.5/10

What are the people in charge doing?

top 45% of 91 in its family for leadership; chief executive since 2016.

weight 22% of this tense · 55th percentile among 91 sector filers · read for its shareholders

From the record

Microbot Medical Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Gadot, Harel (Chairman, President and CEO, as filed), filing under that title since 2016-11-30, 10 years (top 22% of its family); the 10 officers and directors filing in the last fifteen months have been on the record a median of 6.4 years (top 33%); 10 officer or director changes were reported on Form 8-K since 2023-11-13, against the 10 people in charge now (bottom 19%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

What it rests on

  • officer and director changes on Form 8-K, against the people in charge10 in three years among 10 peoplebottom 19% of its family
  • the median years the people in charge have filed6.4 yearstop 33% of its family
  • the chief executive's years on the record10.0 yearstop 22% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

▶ Future

What are they set up to do next?

2.4/1030% of the headline grade · 1 of 3 filed, 2 estimated

Room to expand

SI estimate
4.0/10

How much room does it have to grow?

SI estimate 4.0/10, confidence 35 of 100 (one part).

weight 45% of this tense · 40th percentile among 120 sector filers · read for itself

SI estimate Inferred, not read as filed

Why it is an estimate
Read from one part only, cash less debt against assets, which ranks in the bottom 40% of 120 in its family; the record does not carry two of the four parts: cash less debt against assets, cash from operations less capital spending against revenue, gross margin, research against revenue.
What the record cannot read
The record does not carry two of the four parts: cash less debt against assets, cash from operations less capital spending against revenue, gross margin, research against revenue.
How it was reasoned
one part: cash less debt against assets, the one part on file, ranked among 120 in its family.
Confidence
35 of 100
What would change it
A filing that carries the missing parts replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Microbot Medical Inc.'s room to expand is put at 4.0 of 10 with a confidence of 35 of 100, because read from one part only, cash less debt against assets, which ranks in the bottom 40% of 120 in its family; the record does not carry two of the four parts: cash less debt against assets, cash from operations less capital spending against revenue, gross margin, research against revenue. A filing that carries the missing parts replaces this estimate with the filed reading.

Growth drivers

as filed
1.8/10

What could actually drive growth from here?

bottom 18% of 105 in its family for growth drivers.

weight 33% of this tense · 18th percentile among 105 sector filers · read for its customers

From the record

Microbot Medical Inc.'s growth drivers, from the filed years to fiscal 2015: revenue grew -56% a year over the last three filed years against -30% over all 7, slowing (bottom 9% of its family); the newest year grew -86.3% (bottom 2%); research spending grew -6.7% a year (bottom 23%); capital spending grew -10.6% a year (bottom 39%) (its annual reports). Microbot Medical Inc. tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.

What it rests on

  • three-year growth against the whole span-26.0 points a yearbottom 9% of its family
  • the newest year's revenue growth-86.3%bottom 2% of its family
  • three-year growth of research spending-6.7%bottom 23% of its family
  • three-year growth of capital spending-10.6%bottom 39% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Expectations vs reality

SI estimate
0.2/10

Did its newest year beat what its own record pointed to?

SI estimate 0.2/10, confidence 35 of 100 (one part).

weight 22% of this tense · 2nd percentile among 92 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate
Read from one part only, revenue against the prior three years' pace, which ranks in the bottom 2% of 92 in its family; the record does not carry four filed years of revenue and two of the three parts: revenue against the prior pace, earnings against the prior average, the margin change.
What the record cannot read
The record does not carry four filed years of revenue and two of the three parts: revenue against the prior pace, earnings against the prior average, the margin change.
How it was reasoned
one part: revenue against the prior three years' pace, the one part on file, ranked among 92 in its family.
Confidence
35 of 100
What would change it
A filing that carries the missing parts replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Microbot Medical Inc.'s expectations vs reality is put at 0.2 of 10 with a confidence of 35 of 100, because read from one part only, revenue against the prior three years' pace, which ranks in the bottom 2% of 92 in its family; the record does not carry four filed years of revenue and two of the three parts: revenue against the prior pace, earnings against the prior average, the margin change. A filing that carries the missing parts replaces this estimate with the filed reading.

The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made

SI Assistanton MBOT · research, not advice